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PURPOSE. Neuroretinopathy is increasingly being recognized as an independent cause of vision
loss in diabetes. Visual field loss, as detected by frequency doubling technology (FDT)-based
visual perimetry, is a sign of neuroretinopathy and occurs in early stages of diabetic
retinopathy (DR). Here, we hypothesized that FDT visual field testing could identify patients
with diabetic neuroretinopathy in the absence of clinically detectable microvascular DR.
METHODS. All National Health and Nutrition Examination Survey (NHANES) 2005–2008
participants receiving fundus photography and visual field screening by FDT were included in
this study. Participants with self-reported glaucoma, use of glaucoma medications, or
determination of glaucoma based on disk features were excluded. Visual fields were screened
using FDT protocol in which participants underwent a 19-subfield suprathreshold test.
RESULTS. Patients with diabetes but no DR were more likely to have ‡1 subfield defects at 5%,
2%, and 1% probability levels than patients without diabetes (41.3% vs. 28.6%; 27.4% vs.
17.5%; 15.9% vs. 9.4%; all P < 0.0008). Multivariable regression showed that each additional
glycated hemoglobin % (HbA1c) was associated with 19% greater odds of having ‡1 visual
subfield defects in those with diabetes without DR (odds ratio: 1.19, 95% confidence interval:
1.07–1.33; P ¼ 0.0020).
CONCLUSIONS. Patients with diabetes have visual field defects in the absence of clinically
detectable DR, suggesting neuroretinopathy precedes classical microvascular disease. These
defects become more frequent with the onset of visible retinopathy and worsen as the
retinopathy becomes more severe. Longitudinal studies are required to understand the
pathogenesis of diabetic neuroretinopathy in relation to classic DR.
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Diabetic retinopathy (DR), a common microvascular com-plication of diabetes, is directly related to plasma glucose
levels. In fact, current diagnostic criteria for diabetes estab-
lished by the American Diabetes Association (glycated hemo-
globin [HbA1c] ‡ 6.5% or fasting plasma glucose ‡ 126 mg/dL)
are based on plasma glucose levels associated with the
incidence of moderate DR in large, population-based studies.1
Characteristic microvascular lesions and capillary leakage are
the hallmarks of DR. Contemporary treatments of this disease,
including laser photocoagulation, corticosteroids, and even
antagonists of the vascular endothelial growth factor (VEGF)
pathway, target late stages of the disease and may be ineffective
in up to one third of patients. In addition, chronic anti-VEGF
therapy is associated with deleterious effects in clinical settings
and in rodent models.2 Therapies that target the disease process
at earlier stages in the diabetic eye may improve public health.
In preclinical studies and small clinical analyses, functional
visual deficits in diabetes are observed prior to vascular
retinopathy.3–6 These deficits are collectively termed diabetic
neuroretinopathy, and their relationship to classical DR is
incompletely understood. Thinning of the inner retina during
diabetes can be detected by optical coherence tomography, but
changes are often subtle and progressive much like loss of the
optic nerve head rim due to glaucoma. But despite being
challenging to detect, identification of diabetic neuroretinop-
athy could present an opportunity for prevention of the more
vision-threatening vascular lesions in the diabetic retina. Visual
field testing using frequency doubling technology (FDT) was
introduced as a rapid screening tool to identify retinal ganglion
cell loss (specifically of the magnocellular variety) in early
glaucoma,7 but it has also shown some utility in detecting
damage in early DR.3,8 Here, we hypothesized that diabetes
itself (without DR) causes inner retinal visual defects, and that
FDT visual field testing reveals such defects. We report findings
from a secondary analysis of a large cohort representative of the
US noninstitutionalized civilian population showing that
patients with diabetes, but no clinically detectable DR, have
significant FDT-detected field loss and that these patterns of
field loss worsen during the course of classical DR.
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METHODS
Study Population
The study population was gathered from the National Health
and Nutrition Examination Survey (NHANES) 2005–2008,
which used a stratified, multistage probability design to allow
for representation of the US noninstitutionalized civilian
population.9 This work was conducted in compliance with
the Declaration of Helsinki. Cohort selection for this study is
depicted in Figure 1. All participants receiving both fundus
photography (with grading) and FDT visual field testing were
eligible for inclusion in this study. Participants with a self-
report of glaucoma diagnosis or determination of ‘‘possible,’’
‘‘probable,’’ or ‘‘definite glaucoma’’ by three glaucoma
specialists at Johns Hopkins University based on disk features
on fundus photography (such as vertical cup-to-disk ratio ‡
0.6, disk hemorrhage, excavation, notch, and tilt), were
excluded.
Retinopathy scores were extracted from grading of 2-field
nonmydriatic photography of each eye using modified Early
Treatment of Diabetic Retinopathy Study (ETDRS) criteria, as
described previously.10,11 Diabetes mellitus was defined as
present if any of the following criteria were met: (1) self-report
of diabetes in the NHANES questionnaire; (2) HbA1c ‡ 6.5%;
or (3) use of oral or injectable medicines for hyperglycemia.
Protocols for NHANES visual acuity testing have been
described.12 For this analysis, best-corrected Snellen-equivalent
vision was defined as the better of either (1) presenting visual
acuity with current lens prescription or (2) visual acuity after
NHANES-conducted objective refraction.
Visual fields were evaluated in a subset of NHANES
participants aged 40 years and older using FDT perimetry
screening procedures.13,14 Participants underwent a 19-sub-
field suprathreshold screening test in two replicates (conduct-
ed on the same day) using the N-30-5 test on the Humphrey
Matrix FDT (Carl Zeiss Meditec, Dublin, CA, USA). Stimuli were
presented at the age-adjusted 5% probability level. If this was
missed, a target was presented at the 2% probability level, and
if missed, it was presented at the 1% probability level. A test
was considered unreliable if the false positive rate was greater
than 33%, or if there were greater than 33% fixation losses by
physiologic blind spot testing, or if the technician noted any
fixation error.12 NHANES used a stringent 2-2-1 algorithm to
define visual field loss by FDT testing.15 Adopting these
standards, patients in this study were considered to have visual
field loss if they had a defect in at least two subfields on both
the first test and the second test, and if at least one of those
subfields were defective in both tests. In addition to 2-2-1
algorithm-based visual field loss, the mean number of defective
visual fields for each eye per patient was calculated for each of
the three threshold levels (5% or lesser, 2% or lesser, and 1%)
using data from both replicates; the mean number of subfield
defects between both trials were calculated for each eye and
summed to calculate the total number of defects across both
eyes.
Statistical Analysis
Participants were placed in four groups based on diabetes
status and retinopathy severity: (1) no diabetes, (2) diabetes
with no DR, (3) diabetes with mild nonproliferative DR
(NPDR), and (4) diabetes with moderate or severe NPDR, or
proliferative DR (PDR). Baseline characteristics between these
groups were compared using ANOVA for continuous variables
and Rao-Scott v2 test for categorical variables. The number of
participants in each group with 2-2-1 algorithm defined visual
field loss or ‡1, 5, 10, or 15 subfield defects was compared
with Rao-Scott v2 test. Mean number of subfield defects was
compared across all four groups with ANOVA while the mean
number of subfield defects between the diabetes and diabetes
with no retinopathy groups was compared with Hochberg’s
GT2 post hoc test. Agreement between number of subfield
defects between eyes was compared using Cohen’s j.
Multivariable logistic regression was used to evaluate the
association between covariates and the presence of visual field
defects in participants without retinopathy. Lipids were not
included in the multivariable model, because those values were
FIGURE 1. Cohort selection flowchart for NHANES 2005–2008 Participants Aged 40 Years and Older With Fundus Photography and Frequency
Doubling Technology Visual Field Testing.
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only drawn in the fasting group, resulting in missing data for
half of the cohort. Sampling weights provided by the National
Center for Health Statistics, Centers for Disease Control and
Prevention were used. A 2-tailed P-value of <0.05 was
considered significant. All data were analyzed using SAS 9.4
(2012, SAS Institute Inc., Cary, NC, USA).
RESULTS
During 2005–2008, NHANES collected information on 20,497
patients and captured fundus photos and FDT fields on 5651 of
them. Among these, 5482 patients had gradable photos in both
eyes and were eligible for this study. After excluding 503
patients for suspicion of glaucoma (or definite diagnosis of
glaucoma) and 985 patients for unreliable FDT testing, 3994
participants and 7988 eyes were included in the final analysis.
Adjusting for survey weighting design, this sample represents
85,656,498 people in the United States and were 47.1% male,
78.4% Caucasian, 8.7% African American, 5.4% Mexican
American, 7.6% other ethnicities, with a mean age of 55.7
years (SEM: 0.41). Participants with diabetes (with and without
retinopathy) were older, more likely not to be Caucasian, had
higher HbA1c, greater levels of dyslipidemia, and elevated C-
reactive peptide (CRP) compared with patients without
diabetes. Notably, there were no differences in the mean
arterial blood pressure between groups (Table 1).
Participants with diabetes and no DR were more likely than
those without diabetes to have 2-2-1 algorithm defined visual
field loss (Table 2; 8.2% vs. 4.4%; P < 0.0001). Participants with
diabetes and moderate or severe NPDR or PDR were more
likely than all groups to have 2-2-1 algorithm defined visual
field loss (24.0% vs. 9.3% vs. 8.2% vs. 4.4%; P < 0.0001; Table
2). Participants with diabetes but no clinically detectable
retinopathy were more likely to have a total of ‡1 subfield
defects at the <5%, 2%, and 1% probability levels than patients
without diabetes (all P < 0.05; Table 2). In sensitivity analyses,
participants with diabetes and no retinopathy were more likely
to have ‡10 subfield defects at all threshold levels compared
with patients without diabetes (all P < 0.05; Table 2) and were
also more likely to have ‡15 defects at the 2% and 1% test
thresholds, which were the most stringent (all P < 0.05; Table
2). Participants with diabetes and no retinopathy had no
significant differences in the number of subfield defects
compared with participants with mild NPDR. However,
participants with diabetes and moderate or severe NPDR, or
PDR had more subfield defects than all other groups (Table 2; P
< 0.0001). Patients with no diabetes had a mean of 1.9 (95%
confidence interval [CI]: 1.7–2.2) subfield defects at the 5%
probability level, whereas those with diabetes and no DR had a
mean of 3.1 (95% CI: 2.3–3.9) subfield defects (P ¼ 0.0019),
whereas those with diabetes and mild NPDR had 3.5 (95% CI:
1.7–5.3) subfield defects, and those with diabetes, moderate or
severe NPDR, or PDR had a mean of 7.0 (95% CI: 4.8–9.2)
subfield defects at the <5% probability level (P < 0.0001).
There was no difference between the mean number of subfield
defects at the 2% and 1% probability levels comparing patients
without diabetes with those with diabetes but no retinopathy
(P ¼ 0.1678, P ¼ 0.3585; Table 2). Participants showed
substantial agreement between eyes demonstrating ‡1 defects
at the 5% threshold level (j¼0.6030). Seven hundred thirty-six
(18.4%) participants had defects in one eye only at the 5%
threshold level across both FDT test replicates. Participants
showed substantial agreement between two tests demonstrat-
ing ‡1 defects at the 5% threshold level in both the right eye (j
¼ 0.6504) and left eye (j ¼ 0.7046).
In participants without DR, a multivariable logistic regres-
sion model adjusting for age, sex, ethnicity, and CRP showed
that each additional HbA1c percentage point was associated
with a 19% increase in odds of having ‡1 visual subfield defect
at the 5% level (odds ratio [OR]: 1.19, 95% CI: 1.07–1.33; P ¼
0.0020; Table 3). African American ethnicity (OR: 2.23, 95% CI:
1.75–2.85; P < 0.0001) and Mexican American ethnicity (OR:
1.80, 95% CI: 1.26–2.59; P ¼ 0.0023) and older age were
significantly associated with odds of ‡1 visual subfield defect.
Other metabolic parameters related to type 2 diabetes were
investigated for their correlation with visual field defects. In
multivariable logistic regression models controlling for age,
sex, ethnicity, CRP, and HbA1c, triglycerides (mg/dL) (OR:
1.00, 95% CI: 0.99–1.00; P ¼ 0.2694), low density lipoprotein
TABLE 1. Characteristics of the NHANES 2005–2008 Participants Aged 40 Years and Older With Fundus Photography and FDT Visual Field Testing,
by Diabetes Status and Retinopathy Severity
DM DMþ DR DMþ Mild NPDR
DMþ Moderate,
Severe NPDR, PDR P*
n 3243 530 147 74
Mean age, y (95% CI) 54.8 (54.1–55.6) 59.7 (58.3–61.1) 61.4 (59.7–63.1) 58.7 (55.1–62.2) <0.0001
Sex (%)† 0.1301
Male 1606 (46.8) 247 (46.2) 87 (56.4) 41 (54.8)
Female 1637 (53.2) 283 (53.8) 60 (43.6) 33 (45.2)
Ethnicity (%)† <0.0001
Caucasian 1914 (80.6) 224 (66.7) 53 (59.3) 16 (47.9)
African American 535 (7.3) 143 (15.5) 49 (22.2) 33 (32.0)
Mexican American 481 (4.9) 103 (7.7) 31 (8.8) 20 (14.5)
Other 313 (7.2) 60 (10.1) 14 (9.7) 5 (5.6)
HbA1c, % (95% CI) 5.41 (5.39–5.43) 6.98 (6.79–7.17) 7.81 (7.43–8.20) 8.35 (7.55–9.15) <0.0001
MABP, mm Hg (95% CI) 89.7 (89.2–90.2) 90.5 (88.6–92.4) 88.4 (85.9–90.9) 89.8 (85.9–93.7) 0.5119
CRP, mg/dL (95% CI) 0.42 (0.37–0.46) 0.69 (0.54–0.83) 0.51 (0.39–0.62) 0.67 (0.51–0.84) 0.0089
Triglycerides, mg/dL (95% CI) 141.2 (135.4–147.0) 191.6 (150.2–233.0) 180.0 (134.3–225.6) 146.3 (97.4–195.2) <0.0001
LDL, mg/dL (95% CI) 122.0 (119.7–124.3) 104.3 (98.5–110.2) 101.1 (86.9–115.3) 111.9 (88.2–135.7) <0.0001
HDL, mg/dL (95% CI) 54.9 (54.2–55.7) 47.2 (45.6–48.8) 48.8 (46.7–50.8) 48.0 (43.2–52.9) <0.0001
Cholesterol, mg/dL (95% CI) 206.9 (205.2–208.6) 192.5 (187.3–197.7) 185.5 (172.3–198.7) 190.4 (166.9–213.8) <0.0001
DM, diabetes mellitus; DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; MABP,
mean arterial blood pressure; CRP, C-reactive peptide; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
* P values were calculated using ANOVA for continuous variables and the Rao-Scott v2 test for categorical variables.
† Percentages are survey design adjusted.
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(mg/dL) (OR: 1.00, 95% CI: 0.99–1.01; P ¼ 0.8624), total
cholesterol (mg/dL) (OR: 1.00, 95% CI: 0.99–1.00; P¼ 0.4212),
and homeostatic model for insulin resistance (OR: 0.98, 95%
CI: 0.94–1.03; P ¼ 0.4364) were not found to be significant
predictors of having ‡1 visual subfield defect at the 5% level.
Duration of diabetes was also found to not be a significant
predictor (per year OR: 1.00, 95% 0.99–1.00; P ¼ 0.5687).
Between groups, a comparison of field loss across subfields
of the FDT perimeter (Fig. 2A) showed differences in both the
frequency of loss within various subfields and in the overall
patterns of field loss. Individuals with DR had the highest
percentage of participants with a field defects in several of the
19 subfields tested, compared with patients with no retinop-
athy (Figs. 2B, 2D). Notably, these defects tended to occur
symmetrically and preferentially in the nasal visual fields (Fig.
2D). Participants with diabetes and no microvascular lesions
had higher frequencies of field loss when compared with those
without diabetes, and the defects in this group showed a
diffuse pattern (Fig. 2C).
DISCUSSION
This post hoc analysis of a large-scale, national, population-
based survey demonstrates that compared with healthy
controls, FDT visual field defects occur more frequently in
participants with diabetes in the absence of outright retinop-
athy, suggesting an inner retinal sensory neuropathy associated
with diabetes itself. These defects become more frequent with
the onset of visible retinopathy and worsen as the retinopathy
becomes more severe. Furthermore, visual field defects
associated with DR tend to occur in the nasal subfields.
TABLE 2. Number of Participants With 2-2-1 Algorithm Defined Visual Field Loss, or ‡1, 5, 10, or 15 Visual Subfield Defects at Each Threshold Level
by Diabetes Status and DR Severity, NHANES 2005–2008 Participants Aged 40 Years and Older With Fundus Photography and FDT Visual Field
Testing




Severe NPDR, PDR P†
Number of participants with any field loss
as determined by 2-2-1 algorithm
208 (4.4) 49 (8.2) <0.0001 19 (9.3) 19 (24.0) <0.0001
<5% threshold
Number of field defects, n (%)
‡1 1039 (28.6) 214 (41.3) <0.0001 66 (40.4) 46 (64.7) <0.0001
‡5 488 (11.7) 113 (19.7) 0.0003 40 (23.8) 31 (36.1) <0.0001
‡10 276 (6.9) 66 (10.9) 0.0093 23 (11.4) 23 (22.7) <0.0001
‡15 184 (4.4) 34 (5.5) 0.3961 14 (7.2) 17 (16.4) 0.0034
Mean field defects (95% CI) 1.9 (1.7–2.2) 3.1 (2.3–3.9) 0.0019 3.6 (1.7–5.4) 6.8 (4.7–9.0) <0.0001
<2% threshold
Number of field defects, n (%)
‡1 664 (17.5) 151 (27.4) 0.0001 48 (26.6) 38 (47.8) <0.0001
‡5 260 (5.6) 59 (9.7) 0.0005 23 (11.9) 22 (22.2) <0.0001
‡10 141 (3.1) 32 (5.3) 0.0376 12 (6.6) 17 (16.5) <0.0001
‡15 81 (1.7) 19 (3.6) 0.0281 8 (3.8) 12 (10.4) <0.0001
Mean field defects (95% CI) 1.0 (0.8–1.1) 1.7 (1.1–2.4) 0.1678 1.8 (0.7–2.9) 4.6 (2.8–6.3) 0.0012
<1% threshold
Number of field defects, n (%)
‡1 384 (9.4) 93 (15.9) 0.0008 34 (19.1) 26 (31.8) <0.0001
‡5 134 (2.9) 25 (4.3) 0.1593 8 (3.8) 15 (12.8) 0.0010
‡10 62 (1.2) 15 (2.9) 0.0229 7 (3.6) 10 (9.2) <0.0001
‡15 37 (0.7) 11 (2.3) 0.0059 4 (1.2) 8 (6.6) <0.0001
Mean field defects (95% CI) 0.5 (0.4–0.5) 0.9 (0.4–1.4) 0.3585 0.8 (0.2–1.4) 2.5 (1.4–3.6) 0.0038
Best visual acuity 0.1260 0.0656
None (20/20–20/40) 3126 (99.5) 505 (98.8) 138 (98.9) 63 (88.7)
Moderate (20/50–20/80) 29 (0.4) 6 (1.1) 4 (1.1) 5 (11.3)
Severe (‡20/200) 3 (0.1) 1 (0.1) 0 (0) 0 (0)
All percentages are survey design adjusted. DM, diabetes mellitus; DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; PDR,
proliferative diabetic retinopathy.
* P values comparing DM and DMþDR groups reported from Rao-Scott v2 test for categorical variables and Hochberg’s GT2 post hoc test for
continuous variables.
† P values comparing all four groups calculated reported from Rao-Scott v2 test for categorical variables and ANOVA for continuous variables.
TABLE 3. Multivariable Logistic Regression Model For Odds of ‡1
Visual Subfield Defects at 5% Level in Patients Without DR, NHANES
2005–2008 Participants Aged 40 Years and Older With Fundus
Photography and FDT Visual Field Testing
Adjusted OR (95% CI) P
HbA1c 1.19 (1.07–1.33) 0.0020






50–59 1.25 (0.93–1.68) 0.1388
60–69 1.70 (1.25–2.30) 0.0013
‡70 3.21 (2.47–4.18) <.0001
Ethnicity
Caucasian Reference
African American 2.23 (1.75–2.85) <0.0001
Mexican American 1.80 (1.26–2.59) 0.0023
Other 1.53 (1.04–2.26) 0.0313
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One interpretation of these data is that diabetes induces a
sensory neuropathy of the retina, similar to peripheral
neuropathy in diabetes, preceding the onset of visible retinal
microvascular disease. This notion is supported by other
studies using structural and functional analyses of patients with
diabetes but no retinopathy. It is possible we detected early
glaucomatous loss in patients with diabetes, but two features
of our study argue against this conclusion. First, patients with
established glaucoma, use of glaucoma medications, or
funduscopic evidence of glaucoma or suspicion of glaucoma,
based on the standards set by NHANES, were excluded from
the study. Second, the visual defects in patients with diabetes
are related to the severity of DR—a feature not consistent with
glaucomatous field loss.
Neural deficits occur in patients with diabetes and no
clinically significant DR. Jackson et al.3 describe a 2.9-dB loss in
central sensitivity in a group of 23 patients with diabetes (48%
type 1 diabetes) without NPDR compared with a control group
without diabetes using FDT (P ¼ 0.0002). Parravano et al.4
found that patients with type 1 diabetes and no retinopathy
had more Humphrey Matrix perimetry defects when compared
with controls. These previous clinical studies using perimetry
testing in diabetes included high proportions of patients with
type 1 disease. In contrast, 95% of the population included in
this study is estimated to have type 2 diabetes, reflective of the
surveyed population.16 Therefore, our findings are novel in
describing FDT visual field loss in a predominantly type 2
diabetes population without retinopathy.
Mechanisms underlying vision loss in patients with diabetes
without DR are poorly understood. Sohn et al.6 reported
thinning of the nerve fiber layer, ganglion cell layer, and inner
plexiform layer as measured by optical coherence tomography
prior to the onset of microvascular disease in their longitudinal
study of 45 patients with diabetes. Diabetes is also associated
with histologic evidence of retinal ganglion cell apoptosis.17,18
In experimental models of diabetes, the retina shows reduced
responsivity to insulin,19 and therefore diabetes-associated
retinal thinning and neural loss could be explained by loss of
an important source of neurotrophic support.
A caveat to this study is that the cross-sectional nature of
NHANES survey data limits attempts to draw conclusions on
causal pathophysiology. Although this study shows functional
visual deficits associated with diabetes in the absence of overt
retinopathy, subclinical microvascular lesions—undetectable
by current imaging—may be responsible. This study cannot
definitively conclude whether diabetic neuroretinopathy or DR
occur in parallel or in sequence. However, strengths of the
present analysis include a large sample size, nationally
representative sample, independent grading of fundus photog-
raphy, and high reliability of visual field data acquired.
In summary, these data demonstrate significant inner
neuroretinopathy in diabetes occurring in the absence of
typical microvascular lesions. Longitudinal studies are required
to understand the pathogenesis of diabetic neuroretinopathy
and classic DR.
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